**FasL** and **FADD** delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors

Ivy A Ho1, Wai H Ng2, Paula Y Lam1,3,4*

**Abstract**

**Background:** Glioblastoma multiforme is the most malignant cancer of the brain and is notoriously difficult to treat due to the highly proliferative and infiltrative nature of the cells. Herein, we explored the combination treatment of pre-established human glioma xenograft using multiple therapeutic genes whereby the gene expression is regulated by both cell-type and cell cycle-dependent transcriptional regulatory mechanism conferred by recombinant HSV-1 amplicon vectors.

**Results:** We demonstrated for the first time that Ki67-positive proliferating primary human glioma cells cultured from biopsy samples were effectively induced into cell death by the dual-specific function of the pG8-FasL amplicon vectors. These vectors were relatively stable and exhibited minimal cytotoxicity in vivo. Intracranial implantation of pre-transduced glioma cells resulted in better survival outcome when compared with viral vectors inoculated one week post-implantation of tumor cells, indicating that therapeutic efficacy is dependent on the viral spread and mode of viral vectors administration. We further showed that pG8-FasL amplicon vectors are functional in the presence of commonly used treatment regimens for human brain cancer. In fact, the combined therapies of pG8-FasL and pG8-FADD in the presence of temozolomide significantly improved the survival of mice bearing intracranial high-grade gliomas.

**Conclusion:** Taken together, our results showed that the glioma-specific and cell cycle-dependent HSV-1 amplicon vector is potentially useful as an adjuvant therapy to complement the current gene therapy strategy for gliomas.

**Background**

Glioblastoma multiforme (GBM) accounts for more than 70% of all primary central nervous system neoplasms in adults [1]. Despite advances in surgery, chemotherapy, and radiotherapy, the life expectancy of patients with GBM is still less than 1 year [2]. The failure of current therapeutic approaches to treat GBM is attributed to the high proliferative and infiltrative nature of these neoplasms [3]. Malignant cells are often seen surrounding the neurons and blood vessels and migrate through the white matter tracts to regions distant from the original tumor mass, thus the incidence for tumor recurrence is high. Herein, we explored the combination treatment of pre-established human glioma xenograft using multiple therapeutic genes whereby the gene expression is regulated by the status of cellular proliferation of the cancer cells.

We have previously constructed a Herpes Simplex Virus type 1 (HSV-1)-based amplicon vector in which the activation of the transgene expression is regulated by a G0/G1-specific transcriptional repressor protein termed cell cycle-dependent factor 1, CDF-1 [4]. CDF-1 repressor protein binds to the CDE/CHR regulatory region located within the cyclin A promoter. In quiescent cells, the transactivation of cyclin A promoter could not take place due to the binding of the CDF-1 repressor protein onto the cyclin A promoter. However,
in actively proliferating cells, transcription of the luciferase reporter [4,5] or therapeutic gene [6] is activated due to the absence of the CDF-1 repressor protein. As a proof-of-concept, we have chosen the Fas ligand (FasL) and the Fas-associated death domain (FADD/MORT1) as therapeutic genes because it is important that the effects derived from these genes should not mask the cell cycle-dependent function of the amplicon viral vectors.

Fas ligand/APO-1L (CD95L) is a ~ 40 kDa type II membrane protein belonging to the tumor necrosis factor (TNF) family. Full length FasL can be further processed to release a functional soluble 26 kDa molecule known as soluble FasL [7]. Binding of FasL to its receptor Fas triggers the trimerization of the Fas receptors and initiates the recruitment of the cytoplasmic adaptor protein FADD through the interaction of the death domains [8]. Recruited FADD then interacts with procaspase-8 via the death effector domain to form the death-inducing signaling complex (DISC). The close proximity of caspase-8 zymogens facilitates their autocatalytic cleavage, which subsequently trigger the downstream effector caspases resulting in apoptosis [7,9].

Both Fas and FasL expression are absent in normal astrocytes; however, the expression of Fas, but not FasL, in astrocytomas appear to correlate with neoplasm grade [10-12]. Based on these findings, the Fas/FasL receptor system has been proposed as specific target for human brain tumor therapy. This contradicts another school of thought where the Fas/FasL receptor interaction grant the tumor cell an immune-privileged status, supported by studies demonstrating that the FasL expression in cancer cells deliver death signals to activated Fas-positive T lymphocytes [13-15]. Aside from the possible role in immune surveillance, some of the glioma cells are resistant to Fas-induced apoptosis [16,17], possibly due to low levels of Fas expression [16,18], or absence of FADD [19] or caspase 8 expression [20]. Alternatively, epigenetic aberrations can select for glioma cells that possess several resistance mechanisms to conventional therapies [21]. Interestingly, the overexpression of caspase 8 or FADD has been demonstrated to rescue the defect and rendered the cells sensitive to FasL-induced apoptosis [19,22]. Recently, inducible FADD was also shown to induce apoptosis in resistant glioma cells [18].

Since the Fas/FasL receptor pathway converges at FADD, we hypothesized that the overexpression of FADD could sensitize glioma cells to FasL-induced apoptosis. In view of the multifaceted roles of FasL and FADD in keeping the homeostasis of immune cells, these genes were inserted into a previously generated cell-cycle regulatable HSV-1 amplicon vector under a glial cell-specific GFAP promoter. We demonstrated that the newly generated therapeutic vectors are capable of inducing cell death in proliferating primary human glioma cells derived from patients, suggesting that these vectors are functional in a clinical scenario. Furthermore, these vectors are stable, elicit minimal immune response, and are not significantly hampered by chemotherapy or irradiation in vivo. More importantly, we showed that the co-expression of FasL and FADD could elicit potent anti-tumor effect, which was enhanced in the presence of temozolomide, resulting in prolonged survival of mice bearing orthotopic gliomas. Taken together, our results demonstrated that the glial-specific, cell cycle-regulatable HSV-1 amplicon viral vectors may prove useful in enhancing the efficacy of glioma treatment.

Results
pG8-Fasl amplicon viral vectors induced apoptosis in human glioma cells in a glial cell-specific and cell cycle-dependent manner

Previously, we reported a HSV-1-based amplicon viral vector (denoted as pC8-36; Additional file 1) that mediated luciferase reporter activities in a cell cycle-dependent manner. These vectors were later demonstrated to exhibit cell cycle-dependent therapeutic efficacy when the luciferase reporter gene was substituted by the FasL gene [6]. To further investigate whether the therapeutic gene expression can be restricted not just in dividing cells, but also in glial fibrillary acidic protein (GFAP)-expressing glial cells, the ubiquitous CMV promoter in pC8-Fasl amplicon vector (Additional file 1) was swapped with the astrocyte-specific GFAP enhancer elements and the minimal CMV promoter. The newly derived vector was named pG8-Fasl (Figure 1A). In rapidly dividing GFAP-expressing cells, the glial cells-specific promoter is activated resulting in the transcription of the Gal4/NF-YA fusion protein. The fusion protein will transactivate the minimal cyclin A promoter through its binding to the Gal 4 DNA binding sites, thus mediating FasL protein expression in proliferating glial cells. The pHG8GalFasl construct, which lacked the Gal4/NF-YA fusion gene, served as a control vector (Figure 1B). To confirm the cell-type specific transcription, human glioma cells ΔGli36 and non-glioma cells, HeLa, were chosen because they exhibited similar transduction efficiency when infected by the different types of HSV-1-based amplicon viral vectors (data not shown). As shown in Figure 1C, approximately 20 % higher cell death was observed in proliferating pG8-Fasl-transduced ΔGli36 cells in comparison to the G₁-arrested cells. On the other hand, similar levels of apoptosis was detected in ΔGli36 cells infected with either pHG8GalFasl (Figure 1B) or pG8-Fasl under the growth arrest conditions. This result suggested that the observed cell death is
non-specific, and most likely due to the combined effect of low serum and lovastatin that has been shown to induce apoptosis [23]. By contrast, the pG8-FasL amplicon viral vectors appeared to have lost its activities in HeLa cells, presumably due to the absence of specific cellular factors that are required for the GFAP-containing promoter to be functional (Figure 1C, right panel).

These results were in agreement with the higher level of Fasl expression detected in the proliferating ΔGli36 cells (Figure 1D), providing further evidence that the Fasl expression was regulated in a cell cycle-dependent and glial cell-specific manner.

To demonstrate that pG8-FasL could confer glial cell-specific transgene expression in vivo, both pG8-FasL and pC8-FasL amplicon viral vectors were used in mice bearing xenografts of two different cell type origins. The latter vector, which consisted of the CMV promoter driving the Gal4/NF-YA fusion gene, served as positive control because it has been shown to induce apoptosis in all proliferating cell type [6]; on the contrary, pC8-36 and pG8-18 vector (Additional file 1), which expressed the luciferase reporter protein, served as negative control for pC8-FasL and pG8-FasL, respectively. The pC8 series of vectors contained the luciferase reporter gene under the control of a minimal cyclin A promoter downstream of a ubiquitous CMV promoter; while the pG8 series of vectors conferred glioma-specific transgene expression, both vectors conferred cell cycle-dependent transgene expression.

Amplicon viral vectors (i.e., pG8-18, pG8-FasL, pC8-36, and pC8-FasL; 2 × 10^6 transduction units (TU))
were injected into immunodeficient mice harboring either HeLa-derived or ΔGli36-SCID8-derived tumors. The latter was used due to its consistency in the induction of tumor growth in immunodeficient CB-17 SCID mice. Similar to ΔGli36 cells, this derivative is also sensitive to FasL-induced apoptosis and has more aggressive tumor growth kinetics in immunodeficient mice (data not shown). Administration of viral vectors was performed at a 10-day interval based on our previous findings [6]. Our results demonstrated that pG8-FasL (red color) effectively suppressed tumor growth in mice bearing ΔGli36 glioma xenografts when compared with tumors injected with the pG8-18 amplicon viral vectors (black; p = 0.007; Figure 1E, left panel). Similar trend was not observed in mice bearing HeLa xenografts. At the final measurement, the tumor volumes in pG8-FasL-injected ΔGli36 tumors ranged between non-detectable to 69.06 mm³, whereas the tumor volume in pG8-FasL-injected HeLa tumors ranged between 282.52 mm³ and 500.09 mm³. In both cell types, tumors injected with pC8-FasL (purple) were significantly smaller in size when compared to tumors injected with pC8-36 (blue). This result demonstrated that the expression of the FasL gene under the ubiquitous CMV promoter induced a uniform suppression in the growth of both cell types. Thus, the cell death mediated by pG8-FasL is restricted to proliferating tumor cells of glial origin.

**Therapeutic efficacy of pG8-FasL amplicon vector on primary human glioma cells**

Since many of the GBM-derived cell lines have been propagated in the laboratory for an extensive period of time, we further challenged the clinical application of our viral vectors by testing their functional abilities in primary glioma cells that were isolated directly from the operating theatre. By doing so, we excluded any possible artifact originating from long-term culture in vitro, and provided a better evaluation of our viral vectors in a setting that closely resembled the clinical samples in term of preserving the heterogeneous characteristics of glioma cell phenotypes. These primary cultures of human patient-derived glioma cells exhibited constant proliferation rates for a few passages in vitro as shown by the positive immunoreactivity with the cellular proliferation marker, Ki67 (Figure 2A, top panel). They also retained the glial cell-specific marker, GFAP (Figure 2A; middle panel), and can be easily infected by the amplicon viral vectors (MOI of 0.8) as shown by the high percentage of enhanced green fluorescent protein (eGFP) positive cells observed (~77%; Figure 2A). FasL expression in the primary human glioma cells resulted in approximately 30 % cell death (Figure 2B) in pG8-FasL-infected cells in comparison to those infected with the pG8-18 amplicon vector, which was further confirmed in the TUNEL staining whereby only pG8-FasL-infected cells (eGFP+) were TUNEL positive (Figure 2C). By contrast, pG8-18 infected cells exhibited minimal cell death (Figure 2B and 2C). Taken together, we have clearly demonstrated that the pG8-FasL amplicon viral vectors induced apoptosis not only in GBM-derived cell lines but also in proliferating primary human glioma cells.

Next, we investigated whether the therapeutic efficacy mediated by pG8-FasL could be enhanced by another pro-apoptotic gene such as FADD since the Fas/FasL receptor pathway converges at FADD. As shown in Figure 2D, the co-expression of FasL and FADD resulted in the highest level of cell death observed. Cell death induced by pG8-FasL and pG8-FADD was higher than those observed in pG8-18 infected cells by approximately 3.1-fold and 1.8-fold respectively. The co-expression of FasL and FADD further increased apoptosis by 2.3-fold and 1-fold relative to pG8-FADD or pG8-FasL alone, respectively. Taken together, these results showed that the co-expression of FasL and FADD synergistically enhanced apoptosis in primary human glioblastoma cells.

**Co-expression of FasL and FADD in vivo prolonged the survival of orthotopic glioma-bearing mice**

Based on the results above, we decided to investigate whether the synergistic effect of FasL and FADD in enhancing apoptosis could be recapitulated in vivo. In Paradigm 1, ΔGli36 human glioma cells were pre-infected with equal ratios (5×10⁵ TU each) of pG8-FasL and pG8-FADD amplicon viral vectors followed by implantation into the right hemisphere of immunodeficient mice on the next day (Figure 3A). The viability of ΔGli36 cells were confirmed by both trypan blue as well as TUNEL assays (Additional file 2) prior to intracranial implantation. In Paradigm 2, equal ratios (5×10⁵ TU each) of pG8-FasL and pG8-FADD amplicon viral vectors were injected into pre-established ΔGli36 tumors one week after tumor implantation (Figure 3B). As expected, co-expression of both FasL and FADD prolonged the median survival time of ΔGli36 tumor-bearing mice. For Paradigm 1, the median survival time of mice were improved by 57 % from 19 days (control group) to 30 days, with 2 mice surviving past 30 days but eventually succumbed at days 43 and 49 (p = 0.0081 by log-rank; Figure 3A). By contrast, direct intratumoral injection of pG8-FasL and pG8-FADD into pre-established glioma resulted in a reduced but significant overall survival of 37.5% (p = 0.0163 by log-rank; Figure 3B). PCR analysis confirmed the presence of the amplicon virions based on the eGFP marker gene. To understand if the difference observed between the two paradigms may be due to possible differences in the transduction efficiency, the percentage of viral vectors infected cells
(as marked by the presence of eGFP) were examined in both scenarios. In Paradigm 1, approximately 95% of α-Gli36 cells were efficiently infected at an MOI of 2.0 in vitro (Additional file 2). By contrast, direct inoculation of the viral vectors resulted in approximately 17.83% of the glioma cells positive for eGFP (Figure 3Cii). The observed difference may be due to the poor spreading of these vectors or that the vectors were inoculated into region of necrosis or hypoxia that is unfavorable for infection. Thus, we first determined the extent of the viral spread by estimating the area covered by eGFP+ cells in representative cryosections. The estimated area of spread, based on the formula \( \pi r_1 r_2 \) (where \( r_1 \) and \( r_2 \) represent radii of the eGFP section; Figure 3Ciii), was approximately 0.53 mm², which was less than 0.5% of an average coronal mouse brain section, indicating that the limited vector spread resulted in a lower transduction efficiency. Next, we examined whether these virions were less stable in the tumor-bearing region of the mouse brain. To address this issue, similar amount of viral vectors (1 × 10⁶ TU) was administered into the normal and glioma-bearing hemisphere of the mouse brain. At different time points, the brains were removed and analyzed for the presence of the luciferase gene. As shown in Figure 3D, luciferase gene was detectable in both hemispheres up to day 28, indicating the stability
Figure 3: Effect of FasL and FADD expression in human glioma xenograft in vivo. Kaplan-Meier survival analysis of mice receiving (A) ΔGlI36 cells preinfected with pG8-Fasl and pG8-FADD, (B) intracranial injections of pG8-Fasl and pG8-FADD into pre-established ΔGlI36 tumor in comparison to controls (n = 5). PCR analysis performed on Hirt’s DNA isolated from the mouse brain using primers against the exogenous eGFP gene and normalized using 18S. (C) Flow cytometry analysis of the percentage of eGFP+ cells in mice injected with 1 x 10^6 TU of (ii) pG8-18 amplicon vectors in comparison to (i) control. (iii) Photomicrograph of brain section showed the spreading of the pG8-18 viral vector. Image was captured using a 20×/N.A 0.50 Plan Fluor lens mounted on an Axioimager inverted microscope. r1 and r2 are the distance from the center of the eGFP+ region. The area of dispersion was calculated using the LSM Image browser (Zeiss) based on the formula for ellipse area = π*r1*r2. (D) PCR analysis performed on Hirt’s DNA isolated from the non-tumor-bearing hemisphere (N) and the tumor-bearing hemisphere (T) of a mouse brain injected with pG8-18 amplicon viral vectors. PCR was performed using primers specific for luciferase and 18S. (E) Immunohistochemistry images showing the immunogenicity of pG8-18 amplicon viral vectors (1×10^6 TU) inoculated into immunocompetent Balb/c mice. Sections were stained for CD4, CD8 and CD11b on days 1 and 4 post-injection and counterstained with methyl green. Images shown are original magnification x200.
of the amplicon viral vectors in vivo. We did not check for the presence of the luciferase gene over longer time point because mice bearing the ΔGli36 glioma xenograft succumb to brain tumors after 1 month. Although HSV-1 amplicon viral vectors have been reported in several studies to exhibit minimal cytotoxicity due to the absence of the helper viruses, the presence of exogenous elements such as the yeast Gal4 protein and the mouse NF-YA proteins from the pG8-based amplicon viral vectors could potentially generate antigenic peptides that elicit an immune response from the residual nonspecific immune system of the nude mice, which may subsequently also affect the therapeutic outcome in Paradigm 2. To exclude this possibility, pG8-18 amplicon viral vectors (1× 10⁶ TU) were intracranially administered into immunocompetent Balb/C mice. In parallel, similar volume of PBS was injected into the same region of the mouse brain in the control mice. All mice were sacrificed either on day 1 or 4 post-viral transduction. The activation of the immune response was determined by immunohistochemistry staining for T lymphocytes (CD4 and CD8) and microglia (CD11b) infiltration. CD4, CD8 and CD11b expression were detectable one day post-injection (Figure 3E) in both PBS and pG8-18-injected mice, indicating that both PBS and pG8-18 viral vectors induced inflammatory responses, possibly due to the transient disruption of the blood brain barrier. However, immunoreactivity from the three markers was not detectable at day 4 in neither group of mice, suggesting that pG8-based viral vectors are also relatively non-immunogenic. Taken together, these results demonstrated that the pG8-based viral vector is relatively stable and non-immunogenic in vivo and that the lower therapeutic efficacy observed in Paradigm 2 is due to limited vector spread and mode of vector delivery.

**pG8-18 amplicon vector remains functional after treatment with Temozolomide or γ-irradiation**

Temozolomide (TMZ) is a monofunctional alkylating agent with a favorable toxicity that is commonly used in the treatment of recurrent glioma [24]. Ionizing radiation (IR) therapy has also been adopted as a choice of treatment for malignant gliomas [25]. Together, they conferred survival benefit in patients with GBM and have become part of a new standard of care for GBM patients [26]. Given that our viral vectors (pG8-18-based vectors) mediated therapeutic gene expression specifically in proliferating glial cells, they are best suited as an adjuvant therapy to kill residual dividing glioma cells that have not been completely removed during surgery, radiation or chemotherapy. Thus, we extended our previous studies to examine the functionality of pG8-18 amplicon vectors in the presence of either treatment. Human glioma ΔGli36 cells were infected with either pG8-18 or the control amplicon viral vector pH8GalLuc followed by treatment with TMZ. In agreement with published literature [27], we observed an accumulation of cells in the G2/M phase (from 24-26 % to 45-51 %) of the cell cycle when the cells were treated with TMZ (data not shown). Although we observed a decline in the luciferase reporter activities in pG8-18-transduced TMZ-treated cells when compared with the pG8-18-transduced untreated cells, similar trend was also observed in cells infected with control pH8GalLuc vectors (Figure 4A), suggesting that the lower luciferase activity is probably due to the general cytotoxic effect seen in most chemotherapy drugs. Importantly, the overall luciferase activities mediated by pG8-18 is still significantly higher (511-fold) than TMZ-treated glioma cells transduced by the control pH8GalLuc vectors (Figure 4A). Based on these observations, we concluded that the amplicon viral vectors are functional in the presence of TMZ.

Next, we examined whether DNA damaging γ-irradiation will lead to the loss of previously characterized cell cycle-dependent transgene activation conferred by pG8-18 vectors [4]. To minimize potential virus-specific interference, we have chosen to transfect the ΔGli36 human glioma cells with pG8-18 amplicon vectors, followed by 3 Gy of γ-irradiation. As shown in Figure 3B, significant differences in luciferase activities were not observed between the untreated and the irradiated cells transfected with pG8-18, both in the asynchronized and in the G1-arrested populations. Furthermore, IR did not severely hamper the cell cycle-regulated luciferase gene expression mediated by pG8-18; the luciferase expression was significantly higher in the IR-treated asynchronized cells (82.45 RLU/μg) compared with IR-treated G1-arrested cells (16.28 RLU/μg) (Figure 4B). Our results showed that γ-irradiation did not negatively affect the cell cycle-regulated luciferase expression mediated by the pG8-18 vector. Taken together, these results confirmed that pG8-18-based amplicon vector could be used in combination therapies involving TMZ/IR or both.

To determine whether concurrent treatment of the therapeutic vectors, pG8-Fasl and pG8-FADD, with TMZ or IR or both could induce an even greater extent of cell death, ΔGli36 glioma cells were pre-infected with MOI of 1.0 of pG8-Fasl and pG8-FADD amplicon viruses, followed by treatment with TMZ, IR or both. In parallel, pG8-18-infected cells were treated the same way and used as controls. Our results showed that the percentage of cell death induced by the pG8-18 with TMZ (24.8 %) or IR (24.7 %) alone was lower in comparison to pG8-Fasl/FADD amplicon viruses (37.6 %; Figure 4C). However, when the pG8-Fasl/FADD was introduced together with TMZ and IR, the apoptotic
activity of pG8-FasL/FADD was significantly enhanced from 37.6 % (untreated) to 62 % (TMZ), 66 % (IR) and 95.5 % (TMZ/IR), respectively (Figure 4C). These results showed that TMZ and IR further increased the efficacy of FasL and FADD in vitro.

**Double arm therapy using pG8-FasL/FADD with TMZ prolonged the survival of glioma-bearing mice**

To confirm the observed enhanced efficacy of pG8-FasL and pG8-FADD in the presence of TMZ and IR in vivo, the amplicon viruses were administered one week post-tumor cells implantation subcutaneously. The follow day, TMZ was given for a period of 5 days at 10 mg/kg/day, and IR was administered at 2 Gy/day for the same period of time (Additional file 3). Our results showed that the pG8-FasL and pG8-FADD amplicon viruses could effectively suppressed the tumor growth for about 1 week post-injection. However, the anti-tumor effect was lost as the tumor grew in size, which was anticipated since these amplicon viruses are defective in replication. Mice treated with both amplicon viruses and IR resulted in tumors about 1/4 the size of control alone. Complete tumor regression was observed in animals injected with pG8-FasL/FADD followed by combined treatment with TMZ and IR. So far, the data are in agreement with our earlier *in vitro* findings. Contrary to our expectation, the group of mice treated with pG8-FasL/FADD and TMZ also had tumors that regressed completely. We attributed the latter to the high dose of TMZ used that had efficiently masked the precise therapeutic effect of the amplicon viruses. Since post-treatment with IR exhibited minimal effectiveness in this experiment, we decided to focus our study on evaluating the efficacy of amplicon viruses with TMZ treatment in a clinical relevant mouse model.
Accordingly, pG8-FasL/FADD amplicon viruses were intracranially administered to mice bearing intracranial high grade gliomas as depicted in Figure 5. TMZ (5 daily doses of 5 mg/kg) was administered 8 days post-tumor implantation. As shown in Figure 5, combination treatment of TMZ with pG8-FasL/FADD significantly prolonged the survival of the tumor-bearing mice in comparison to TMZ or pG8-FasL/FADD alone. On the other hand, TMZ, as a single agent, was not as effective as pG8-FasL/FADD in enhancing the survival of tumor bearing mice, albeit the difference between the median survival time for both treatment regimens was not statistically significant. Collectively, our results showed that TMZ can be used in combination with the cell cycle-regulated vector to markedly improve anti-tumor response.

**Discussion**

GBM have retained their dismal prognosis despite advances in neurosurgical techniques, radiation and drug therapies. Some of the difficulties encountered include inaccessibility to resective surgery because of anatomical location and tumor recurrences. Based on a model that predict the number of tumor cells distributed around the primary tumor bed, the percentage of tumor cells found at a distance more than 2 cm from the tumor edge is at ~2 % prior to surgery and increased to ~ 23 % post-surgical resection [28]. Thus, a strategy that can effectively target the highly proliferating tumor cells is urgently in need. We have previously generated a HSV-1 amplicon viral vectors whereby the transgene expression is regulated by cell proliferation [4,6]. The present study aimed to explore the clinical feasibility of this vector in the treatment of human brain tumors by placing the FasL or FADD genes under the regulation of a glial cell-specific promoter. We demonstrated the therapeutic efficacy of these vectors in primary cultures of human brain tumors, and showed their ability to mediate cell-type specific transgene expression in vivo. More importantly, the efficacy of these therapeutic viruses was greatly enhanced by TMZ, resulting in prolonged survival of glioma-bearing mice.

The ligands of the TNF family (e.g, FasL, TRAIL and TNF-α) and the members of the corresponding TNF receptor superfamily are known to exhibit pleiotrophic activities in mammalian cells. They can induce cellular proliferation, differentiation or cell death depending on the responding cell type and the microenvironment [7], for e.g., Fas/FasL interaction has been shown to be involved in neurogenesis [29]; the Fas/FasL system was also demonstrated to confer immune privileged status to tumor cells due to the expression of FasL on the tumor cells and the tumor endothelium [30,31], which induces cell death in the Fas-expressing T cells. However, how this process is regulated is still unknown. Despite these issues, several groups have generated recombinant viral vectors that deliver the FasL gene to eradicate glioma cells and have demonstrated prolongation of survival [32,33]. However, high level of FasL expression has been shown to induce liver failure [34]. Thus, restricting the FasL expression to tumor cells is essential if FasL is to be employed for cancer therapy. We have chosen FasL as our therapeutic gene because in our cell cycle-dependent transgene activation system, the therapeutic effect cannot be overwhelming as this could potentially mask the cell cycle-regulatory property of the vectors. To circumvent the possible complications of the immune system, we have chosen the immunodeficient nude mice as our mouse model; hence, the FasL-induced apoptosis could still serve as a good tool to assess the therapeutic efficacy of our dual-function viral vectors.

Many clinical trials in human brain tumors are conducted by injecting recombinant viral vectors into the tumor cavity margins following surgical resection [35]. It is therefore important that (i) the tumor cells are susceptible to viral infection; (ii) the viruses are stable.
without causing adverse cytotoxic effects; and (iii) the transgene expression is restricted to only tumor cells. We have demonstrated that transduction efficiency of pG8-18 amplicon viruses was relatively high in proliferating GFAP-positive primary human glioma cells. However, the transduction efficiency of HSV-1 amplicon viral vectors has been reported to vary in different primary glioma cell cultures, possibly due to the heterogeneity of the glioma cells and the variation in the cell surface receptors required for viral entry [36]. Thus, it may be necessary to pre-examine the efficiency of infection on a patient’s tumor sample. We have also demonstrated that the amplicon viruses are relatively stable (Figure 3D) although the transgene expression mediated by these vectors may be transient due to the increasing tumor cells to vector ratio. The GFAP enhancer sequence has been shown to confer glial-cell specificity to T98 [37], ΔGli36, U251 and SF767 [4]. Because the GFAP enhancer elements drive FasL and FADD expression specifically in glial cells, the packaging efficiency of the virions was unaffected (data not shown). Furthermore, FasL expression mediated by pG8-Fasl vectors was higher in proliferating versus growth arrested ΔGli36 human glioma cells (Figure 2B), which correlated with the enhanced apoptosis observed in the proliferating GFAP-positive ΔGli36 cells (Figure 2A). By contrast, FasL expression did not differ in the proliferating HeLa cells versus the G1-arrested cells (Figure 1D), indicating that the transgene expression mediated by pG8-Fasl is regulated by type of cells under proliferating conditions. This is further supported by similar finding in vivo (Figure 1E).

One of the major obstacles encountered in targeting death receptors in tumor cells is that the cells are usually resistant to apoptosis induced by death receptor ligands [17,38]. A recent report has shown that CD133-positive cells isolated from human glioma cells are also resistant to Fas-induced apoptosis [39]. Likewise, cells derived from human patients have been shown to be resistant to etoposide, paclitaxel, TMZ and carboplatin [40]. These findings suggest that the immature stem cells in glioma could be an important factor of resistance to Fas signaling pathway. Thus, enhanced therapeutic efficacy is much desired. The co-expression of FADD and caspase-8 are reported to be required for the synergistic cytotoxicity induced by combined IR/TRAIL treatment [41]. As such, we explored whether the therapeutic efficacy of pG8-Fasl could be improved in the presence of FADD. Our results showed that the co-expression of Fasl and FADD in primary glioma cells enhanced apoptosis by 20% in vitro (Figure 2D) and prolonged the survival of intracranial glioma bearing mice (Figure 3A and 3B). However, the therapeutic efficacy varies depending on whether the viruses were used to infect human glioma cells prior to tumor cell implantation (Paradigm 1) or after the establishment of the tumor mass (Paradigm 2). In both scenarios, significantly prolonged survival was observed in mice treated with amplicon viruses albeit paradigm2 was substantially less effective. The latter was attributed to the limited vector spread and mode of vector delivery but not due to the instability of the amplicon virions (Figure 3A, B and 3D) or possible immunocytotoxicity elicited by the vectors (Figure 3E). In fact, Suzuki et al. has reported the persistent transgene expression conferred by HSV-1 amplicon vectors in the brains of immunocompetent C57BL/6 mice (up to 385 days post viral injection) through the incorporation of the Epstein Barr Virus (EBV) episomal elements [42].

TMZ in combination with IR are currently the first-line treatment for recurrent GBM and when used concurrently, have been shown to improve the median survival time of glioma patients for up to 5 years of follow-up [43]. With that in mind, we investigated whether TMZ and IR can improve the overall cell death induced by pG8-Fasl and pG8-FADD amplicon viruses. Indeed, combination treatment of ΔGli36 cells with pG8-Fasl/FADD amplicon viral vectors, TMZ and IR markedly enhanced the percentage of cell death by ~ 40 % (Figure 4C). We further challenged the effectiveness of TMZ and IR in vivo (Additional file 3). This time, the suppressive effect of the therapeutic amplicon viruses was not as remarkable as shown previously (Figure 1E), possibly due to the lower dose of viruses used, a different derivative of glioma cells used and a different strain of mice (SCID mice versus nude mice). Despite these variable parameters, pG8-Fasl/FADD amplicon viruses can still mediate a suppressive effect on the tumor growth. Irradiation, however, did not significantly enhance the overall therapeutic efficacy mediated by the pG8-Fasl/FADD viruses (Additional file 3). This is similar to a report by Yamini et al in that IR alone with adenovirus-delivered tumor necrosis factor (TNF) did not improve the survival of glioma-bearing mice [44]. Since the concomitant and adjuvant dosage of TMZ and IR with pG8-Fasl/FADD is difficult to manipulate in vivo, we decide to focus our study on the effect of TMZ and pG8-Fasl/FADD in mice bearing intracranial gliomas, which are of more clinical relevance. Our results showed that adjuvant TMZ boosted the therapeutic efficacy of pG8-Fasl/FADD; the survival time was markedly prolonged in comparison to mice receiving either TMZ or pG8-Fasl/FADD viruses alone (Figure 5).

The effectiveness of TMZ is largely determined by the status and expression level of the O6-methylguanine-DNA methyltransferase (MGMT) [45]. Silencing of the MGMT promoter has been shown to confer therapeutic benefits by inhibiting DNA repair upon DNA damage.
induced by TMZ [46]. Moreover, Hegi et al showed that the patients with methylated MGMT promoter has better survival than those without after TMZ and IR treatment [47]. Therefore, we speculated that an even greater therapeutic efficacy of pG8-Fasl/FADD and TMZ could be achieved in human glioma cells with generally low MGMT activity. Alternatively, a greater effect may be seen by increasing the viral dosages, or using a more potent therapeutic gene such as the caspase-8 or bacterial exotoxin. Caspase-8 is frequently lost or silenced in human gliomas [20]. Inducible caspase-8 has been shown to be effective in prostate cancer gene therapy [48] and malignant brain tumors [49]. A fusion protein consisting of interleukin 13 (IL-13) and a mutated form of Pseudomonas exotoxin (IL-13-PE) has also been shown to induce potent and specific cytotoxicity in glioma cells that overexpresses the receptor for IL-13, IL13 receptor-α2 (IL13-Rα2) [50]. Since our cell cycle-regulatable HSV-1 amplicon viral vectors have been shown to confer relatively tight regulation of gene expression, it will be interesting to study the potential efficacy in these settings.

From a clinical application point of view, there are two ways one could use these vectors as gene delivery vehicles. They can either be used directly to infect cells surrounding the margins of tumor resection followed by adjuvant/concurrent treatment with TMZ and/or IR, or to infect *ex vivo* cultured adult human mesenchymal stem cells (MSC), which has been shown to be resistant to chemotherapy drugs such as cisplatin, vincristine, and etoposide [51] and IR [52]. Although the latter strategy needs to be stringently evaluated, the inherent tumor tracking properties of MSC is extremely attractive especially since the incidence of metastatic brain tumors with high proliferative potential is predicted to increase [53]. We have performed independent studies to show that HSV-1 amplicon viral vectors can infect MSC efficiently without affecting the cellular proliferation, tumor homing and multilineage differentiation potential of MSC [54]. Thus, further studies are required to couple the homing potential of MSC with the cell cycle-regulatable HSV-1 amplicon vectors.

In summary, we have demonstrated the therapeutic efficacies of pG8-Fasl/FADD amplicon viruses in human glioma cells derived from established cell lines and patients biopsy samples. The vectors are relatively stable with minimal cytotoxicity and remained functional in the presence of chemotherapy and ionizing radiation treatment. More importantly, combined treatments of these therapeutic viruses with TMZ prolonged the survival of intracranial glioma-bearing mice. Given that gliomas are heterogeneous in nature, the combination of TMZ and our cell cycle-regulated Fasl and FADD vector should confer added survival benefits.

**Conclusion**

We have previously constructed a HSV-1 amplicon viral vector in which the transgene expression is regulated by cellular proliferation. In the present study, we demonstrated that Ki67-positive proliferating primary human glioma cells cultured from biopsy samples were effectively induced into cell death by the dual-specific function of pG8-Fasl amplicon vectors. These vectors are cell-type specific in addition to their ability to confer cell cycle-dependent transgene expression. Their efficacies are not hampered by the presence of chemotherapy or irradiation, and are relatively stable and non-cytotoxic *in vivo*. Most importantly, the combined therapies of pG8-Fasl and pG8-FADD in the presence of TMZ significantly improved the survival of mice bearing intracranial high-grade gliomas. In summary, these ampiclon viral vectors are potentially useful as adjuvant therapy to complement the current therapeutic regimens for human gliomas.

**Materials and methods**

**Isolation of primary human glioma cells**

This study has been approved by the SingHealth Centralized Institutional Review Board, Singapore. Primary human glioma cells were isolated, after informed consent, from the brain tumor tissues of patients undergoing brain tumor surgery at the National Neuroscience Institute, Singapore. The harvested tissue was separated into small pieces in the presence of complete medium (Astrocyte Basal Medium (ABM) supplemented with 10% FBS, Penicillin/Streptomycin, normocin and L-Glucose; Cambrex Bio Science Walkersville, Inc., Walkersville, MD). The tissue suspensions were first passed through a 5 ml serological pipette, followed by a 1 ml pipette and finally a flame-polished Pasteur pipette until no clumps were visible. Following trypsin digestion, the homogenate was filtered through a 70-μm cell strainer (BD Biosciences, San Jose CA), and then subjected to centrifugation. The collected cells were cultured in complete ABM. All cells were maintained at 37°C in a humidified incubator with 5% CO₂. The culture of ΔGli36 and HeLa cells was performed as described previously [6].

**Plasmid constructions**

The construction of pG8-18, pH8GalLuc, pC8-36, pC8-Fasl, and pH8GalFasl plasmid were described previously [4,6]. To generate pG8-Fasl, the entire DNA fragment encoding the Gal4/NF-YA fusion protein and the 8GalFasl region from pC8-Fasl vector [6] was excised using PmeI and inserted into the same restriction enzyme site on pG8-18. A similar subcloning strategy was used for the construction of pG8-FADD from pC8-FADD [6]. All plasmids were amplified in *E. coli* STBL-2 (Invitrogen, Grand Island, NY) and the DNA
was extracted using a QIAprep Spin Miniprep kit (Qiagen GmbH, Hilden, Germany) and verified by DNA sequencing (Applied Biosystem Inc., USA).

**Synchonization of cells for cell cycle analysis**

Synchronization of cells in the G1 phase of the cell cycle was performed by treating the cells with 40-60 μM of lovastatin (Merck, Singapore) in the presence of 0.1% FBS for 48 h. Cell cycle analysis was performed as described previously [4].

**Packaging of helper virus free HSV-1 amplicon viral vectors**

Packaging of the HSV-1 amplicon vector was performed as described previously using the helper virus-free packaging method [55]. The titer obtained for the resulting packaged amplicon viral vectors ranged from 1×10⁷ to 1×10⁸ TU/ml after concentration through a sucrose gradient. Infection of viral vectors on ΔGli36 and HeLa cells were performed at a multiplicity of infection (MOI) of 1.0 and the transduction efficiency was determined by flow cytometry for the presence of eGFP+ cells.

**Immunohistochemistry, immunofluorescence and TUNEL staining**

Immunohistochemistry and immunofluorescence staining were performed as previously described [4]. Antibodies (GFAP, Ki67, CD4, CD8, and CD11b) were purchased from BD Biosciences and used at 2 μg/ml concentration. TUNEL staining was performed using the In situ cell death detection kit (Roche) according to manufacturer’s instruction. Briefly, fixed cells were permeabilized with 0.1% triton in 0.1% sodium citrate solution prior to incubation in solution containing the terminal deoxynucleotidyl transferase enzyme and nucleotide mixture. Staining of cells was carried out at 37°C for 1 h. After which, non-specific staining was removed by rinsing the cells in PBS twice. Samples were then visualized under fluorescence microscope. All images were either acquired on the CCD digital camera (Olympus DP11, Olympus, Japan) mounted on the upright microscope (Olympus BX41) or the Nikon TE300 Eclipse fluorescence microscope (Nikon, Japan).

**Treatment with TMZ and γ-irradiation**

Temozolomide (Temodal; Schering Plough, Belgium) was dissolved in DMSO (Sigma Aldrich) to produce a 100 mM stock solution for in vitro experiments. For in vitro experiments, TMZ was diluted with PBS to obtain 75 μM solutions. For in vivo experiments, stock solution was diluted in PBS to a final concentration of 5 mg/ml. A dose of 5 mg/kg body weight was used, which is equivalent to half of the recommended dosage of 25 mg/kg/m² in adult humans [56].

To assess the effect of TMZ treatment on luciferase gene expression, cells were first infected with the respective amplicon viral vectors for 6 h. The transduced cells were divided into two groups, one portion of the cells were cultured in complete medium, while the other portion was treated with 75 μM of TMZ at 37°C. After 1 h of treatment, the cells were rinsed twice with PBS and replenished with complete medium containing 10% serum. To assess the effect of IR, similar procedure was performed as treatment with TMZ, except that the cells were transfected with pG8-18 or pH8GalLuc plasmid. Transfected cells were exposed to 3 Gy of γ-irradiation, followed by incubating the cells in either fresh complete medium or medium containing lovastatin. Luciferase activities were measured after 48 h of transfection.

To assess the effect of TMZ and IR on pG8-Fasl/FADD-mediated cell death, ΔGli36 cells was infected with MOI of 1.0 of pG8-Fasl and pG8-FADD or pG8-18 amplicon viruses. The viral supernatant was removed after 6 h and cells were cultured in medium containing 75 μM of TMZ. The cells were subsequently subjected to 3 Gy of IR treatment. TMZ-containing medium was removed after 1 h of incubation. The percentage of cell death was assessed after 72 h by trypan blue exclusion assay.

**Animal Experiments**

All animal experiments were performed according to the guidelines and protocols approved by the SingHealth Institutional Animal Care and Use Committee, Singapore.

To determine the efficacy of FasL in vivo, 6-8 weeks old CB-17 SCID mice (Animal Resource Centre, Australia), inoculated with either HeLa or ΔGli36-SCID8 cells (2×10⁶) at their right flank, were divided into 4 groups. One day following tumor inoculation, 2×10⁶ TU of viral vector was administered intratumorally. Injections of viral vectors were repeated every 10 days until tumor necrosis was observed in the non-treated groups. The tumor volume was measured and calculated according to the formula volume = 0.52 × length × width². At the end of the experimental period, all animals were sacrificed and tumor nodules were harvested. Analysis of FasL expression was also performed as described previously [6].

To determine the synergistic effect of Fasl and FADD in intracranial tumor-bearing mice, two experimental paradigms were designed. In Paradigm 1, ΔGli36 human glioma cells (1×10⁶) were pre-infected with equal ratios (5×10⁶ TU each) of pG8-Fasl and pG8-FADD amplicon viral vectors followed by implantation into the right hemisphere (bregma (0,0) lateral 2.0 mm and depth 2.5 mm) of immunodeficient nude mice on the next
For Paradigm 2, mice were inoculated with ΔGli36 intracranially followed by inoculation of amplicon viral vectors (MOI of 1.0) intratumorally 7 days later. Mice were monitored weekly for changes in body weight.

For investigating the combined therapeutic effect of TMZ with pG8-Fasl and pG8-FADD in vivo, immuno-incompetent nude mice were first inoculated with 2×10⁵ ΔGli36 cells intracranially. Amplicon viruses, either pG8-18 (2×10⁵ TU) or pG8-Fasl and pG8-FADD (MOI of 1.0, 1×10⁴ TU each), were injected intratumorally (i.t.) into the same co-ordinates after 1 week. TMZ was administered after 18 h and on a daily basis for 5 days (5 mg/kg which total to 25 mg/kg) via an intraperitoneal (i.p.) route.

To assess the effect of TMZ and/or IR on FasL and FADD-mediated tumor regression in a subcutaneous glioma model, mice bearing ΔGli36 human glioma xenograft (5×10⁵) at their hind limbs were randomized into groups indicated in Additional File 3. One week post tumor cell implantation, pG8-Fasl and pG8-FADD amplicon viruses (combined MOI = 1) were injected intratumorally (i.t). Treatment with TMZ, IR or TMZ and IR was initiated 18 h post-virus inoculation. TMZ was delivered i.p. at a dose of 10 mg/kg/day for 5 doses, and IR (2 Gy/day) was given to the mice, which amount to a total of 10 Gy. Tumor volume was measured every 3-4 days as detailed above.

To determine the stability of the pG8-18 amplicon viral vectors in vivo, 1×10⁶ TU of pG8-18 vector was injected into the left (control) and right hemisphere of the same immunodeficient nude mice. The right hemisphere consisted of tumor mass (1×10⁶ ΔGli36), which was implanted a week before viral injection. The brains were then harvested on days 4, 10, and 28 post-injection. The data are presented throughout this study as means ± standard error of the mean. The statistical significance was evaluated by an unpaired t-test, and p < 0.05 was considered significant. Kaplan-Meier survival analysis was used to calculate the percentage of survival as a function of time, and the survival curves were compared using the log-rank test.

### Additional material

**Additional file 1: Schematic diagram of vectors used**

(A) The pC8-36 vector contained the CMV promoter driving the Gal4/NF-YA transactivator in place of the GFAP enhancer element in pG8-18. (B) pC8-Fasl was generated by removal of the luciferase gene from pC8-36 and replaced with the Fasl gene. (C) The pG8-18 vector contained three-tandem repeats of the GFAP enhancer element upstream of the minimal CMV promoter. The pG8-18 amplicon vector consisted of the eGFP gene under the control of the immediate early promoter (IE4/5p) for titrating and monitoring of viral infection. pG8-FADD was generated by swapping the luciferase transgene in pG8-18 with the FADD gene. (D) pIH8Gal4/NF-YA, which lacked the Gal4/NF-YA transactivator sequence, served as a negative control throughout this study.

**Additional file 2: Viability and transduction efficiency of ΔGli36 cells prior to implantation**

(A) TUNEL assay was performed on pre-infected cells to confirm the viability of the cells prior to intracranial inoculation.

(B) The transduction efficiency of ΔGli36 cells pre-infected with pG8-Fasl.
and pGR-FADD prior to tumour implantation was determined by FACS analysis. Image shown was pseudocoloured. Flow cytometry image of infected cells (red) was superimposed on to the image of uninfected cells (green).

Additional file 3: Effect of TMZ and IR on FasL and FADD-mediated tumor regression. The effect of TMZ and/or IR on FasL and FADD-mediated tumor regression was examined in a subcutaneous glialoma model. Mice bearing ΔGl36 human glialoma xenograft (5x10^7) at their hind limbs were randomized into groups indicated and injected with MOI of 1.0 of pG8-FasL/FADD amplicon viruses (u.t.) one week post-tumor cells implantation. Treatment with TMZ, IR or both was initiated 18 h post-virus inoculation. TMZ was delivered i.p. at a dose of 10 mg/kg for 5 doses, and IR (2Gy) was given to the mice daily to a total of 10 Gy. Tumor volume was measured every 3-4 days. Arrow indicated viral inoculation.

List of Abbreviations
eGFP: enhanced green fluorescent protein; FADD: Fas associated protein with a death domain; FasL: Fas Ligand; GBM: Glioblastoma Multiforme; GFAP: Glial fibrillary acidic protein; HSV-1: Herpes Simplex Virus type 1; i.p.: intraperitoneal; IR: irradiation; i.t.: intratumoral; TMZ: temozolomide; TU: transduction unit.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
IH designed and executed the experiments and took part in writing the manuscript; PL was involved in the overall design of the experiments, manuscript; WHN provided the primary human glioma samples together with critical research and development, and wrote the manuscript. All authors have read and approved of the final manuscript.

Acknowledgements
This work was supported by grants from the Agency for Science, Technology and Research (A*STAR) and SingHealth Foundation. We thank Dr. Y. Saeki (Ohio State University Medical Center, Columbus) for providing the pHGCX HSV-1 amplicon vector and the fHSVGL270Δc helper BAC. We would like to express our thanks to Dr. G Wang, Lv Miao, KC Sia, Dr. SF Yap the pHGCX HSV-1 amplicon vector and the fHSV

Author details
1Laboratory of Cancer Gene Therapy, Cellular and Molecular Research Division, Humphrey Cei Institute of Cancer Research, National Cancer Centre, 169610 Singapore. "Department of Neurosurgery, National Neuroscience Institute, 308433 Singapore. "Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, 117597 Singapore. "Duke-NUS Graduate Medical School, 169547 Singapore.

Received: 2 March 2010 Accepted: 13 October 2010

References
1. Oghaki H, Klehecus P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007, 170:1445-1453.
2. Kumar HR, Zhong X, Sandoval JA, Hickey RJ, Malkas LH: Applications of emerging molecular technologies in glioblastoma multiforme. Expert Rev Neurother 2008, 8:1497-1506.
3. Rao JS: Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003, 3:469-501.
4. Ho IA, Hui KM, Lam PY: Glioma-specific and cell cycle-regulated herpes simplex virus type 1 amplicon viral vector. Hum Gene Ther 2004, 15:495-508.
5. Wang GT, Ho IA, Sia KC, Miao L, Hui KM, Lam PY: Engineering an improved cell cycle-regulatable herpes simplex virus type 1 amplicon vector with enhanced transgene expression in proliferating cells yet attenuated activities in resting cells. Hum Gene Ther 2007, 18:222-231.
6. Ho IA, Hui KM, Lam PY: Targeting proliferating tumor cells via the transcriptional control of therapeutic genes. Cancer Gene Ther 2006, 13:44-52.
7. Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
8. Thorburn A: Death receptor-induced cell killing. Cell Signal 2004, 16:139-144.
9. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D: A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995, 270:7795-7798.
10. Tachibana O, Nakazawa H, Lampe J, Watanabe K, Klehecus P, Ogahi K: Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 1995, 55:5528-5530.
11. Husain N, Chocca EA, Rainov N, Louis DN, Zervas NT: Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol 1998, 95:267-270.
12. Strege RJ, Godt C, Stark AM, Hugo HH, Mehdorn HM: Protein expression of Fas, Fas ligand, Bcl-2 and TGFbeta2 and correlation with survival in initial and recurrent human gliomas. J Neurooncol 2004, 67:29-39.
13. Hahne M, Renno T, Schroeter M, Imler M, French L, Bonnard T, MacDonald HR, Tschopp J: Activated B cells express functional Fas ligand. Eur J Immunol 1996, 26:721-724.
14. O’Connell J: Fas ligand and the fate of antitumor cytotoxic T lymphocytes. Immunology 2002, 105:263-266.
15. Andreolla G, Roviti L, Castelli C, Huber V, Perez P, Deho P, Squarcia P, Accornero P, Lozupone F, Lugini A, Stringaro M, Aranica G, Gentile M, Parmiani G, Fais S: Induction of lymphocyte apoptosis by tumor cell secretion of Fas-ligand-bearing microvesicles. J Exp Med 2002, 195:1303-1316.
16. Weller M, Klehecus P, Dichtjans G, Ogahi K: CD95 ligand: lethal weapon against malignant glioma? Brain Pathol 1998, 8:285-293.
17. Riffkin CD, Gray AZ, Hawkings CJ, Chow CW, Ashley DM: Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction. Neuro Oncol 2001, 3:229-240.
18. Karlsson T, Henriksson N, Hedman H: Induction of apoptosis in resistant glioma cells by synthetic caspase-activation. J Neurooncol 2004, 66:71-79.
19. Kondos S, Ishizaka Y, Okada T, Kondo Y, Hitomi M, Tanaka Y, Hqatti T, Barnett GH, Bara BP: FADD gene therapy for malignant gliomas in vitro and in vivo. Hum Gene Ther 1998, 9:1599-1608.
20. Ashley DM, Riffkin CD, Muscat AM, Knight MJ, Kaye AH, Novak U, Hawkings CJ: Caspase 8 is absent or low in many ex vivo gliomas. Cancer 2005, 104:1487-1496.
21. Merlo A: Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev 2003, 26:145-158.
22. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwig SW, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirmanoff RO: Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma. Hum Gene Ther 2002, 13:1015-1025.
23. Chan DT, Chen GG, Poon WS, Liu PC: Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis. J Neurooncol 2006, 76:273-283.
24. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat Rev 1997, 23:35-61.
25. Quack A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M: Current Therapeutic Paradigms in Glioblastoma. Rev Recent Clin Trials 2010, 11:14-27.
26. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
27. Hirise Y, Berger MS, Pieser RO: p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001, 61:1957-1963.
28. Wilson CB: Glioblastoma: the past, the present, and the future. Clin Neurosurg 1992, 38:32-48.
29. Consins NS, Sancho-Martinez I, Launderklos S, Glagov D, Kumar S, Leteiller E, Koch P, Teodorczyk M, Kleber S, Klussmann S, Wiestler O, Brustle O, Koch S, Wiestler O, Brustle O.
Mueller W, Geiffers C, Hill O, Thiemann M, Seedorf M, Grentz N, Sprengel R, Celikel T, Martin-Villalba A. The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell 2009, 5:178-190.

30. Didenko VV, Ngo HN, Minchew C, Basik DS. Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J Neurosurg 2003, 90:65-66.

31. Yu JS, Lee PK, Ehtesham M, Samoto K, Black KL, Wheeler CJ. Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium. J Neurooncol 2003, 64:55-61.

32. Nafe C, Cao Y, Quinones A, Dobberstein KU, Kramm CM, Rainov NG. Expression of mutant non-cleavable Fas ligand on retrovirus packaging cells causes apoptosis of immunocompetent cells and improves prodigig activation gene therapy in a malignant glioma model. Life Sci 2003, 73:1847-1856.

33. Rubinchik S, Yu H, Woraratanaadharm J, Voelkel-Johnson C, Norns JS, Dong JY. Enhanced apoptosis of glioma cell lines is achieved by co-delivering Fasl-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther 2003, 10:814-822.

34. Muruve DA, Nicolson AG, Maniago RF, Strom TB, Sukhatme VP, Libermann TA. Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after Systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Hum Gene Ther 1997, 8:955-963.

35. Sonabend AM, Ulasov IV, Lesnai MS. Gene therapy trials for the treatment of high-grade gliomas. Gene Ther Mol Biol 2007, 11:79-92.

36. Rueger MA, Winkelar A, Miletic H, Kaeoste C, Richter R, Schneider G, Hilk R, Heneka MT, Ernestus R, Hampel JA, Fraefel C, Jacobs AH. Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther 2003, 12:596-596.

37. Chen J, Bezdak T, Chang J, Kherraz AW, Willingham T, Azzara M, Nisen PD: A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res 1998, 58:3504-3507.

38. Weller M, Free K, Groccuth P, Kammers PH, Yonekawa Y, Fontana A: Improved HSV-1 amplicon packaging in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther 2003, 12:596-596.

39. Chen J, Bezdak T, Chang J, Kherraz AW, Willingham T, Azzara M, Nisen PD: A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res 1998, 58:3504-3507.

40. Bertrand J, Begaud-Grimaud G, Bessette B, Verdier M, Battu S, Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Improved HSV-1 amplicon packaging in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther 2003, 12:596-596.

41. Nagane M, Cavenee WK, Shiokawa Y: The sensitivity of human mesenchymal stem cells to ionizing radiation. J Neurosurg 2003, 99:297-300.

42. Suzuki M, Chiocca EA, Saeki Y: Expression of mutant non-cleavable Fas ligand on retrovirus packaging cells causes apoptosis of immunocompetent cells and improves prodigig activation gene therapy in a malignant glioma model. Life Sci 2003, 73:1847-1856.

43. Rubinchik S, Yu H, Woraratanaadharm J, Voelkel-Johnson C, Norns JS, Dong JY. Enhanced apoptosis of glioma cell lines is achieved by co-delivering Fasl-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther 2003, 10:814-822.

44. Muruve DA, Nicolson AG, Maniago RF, Strom TB, Sukhatme VP, Libermann TA. Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after Systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Hum Gene Ther 1997, 8:955-963.

45. Sonabend AM, Ulasov IV, Lesnai MS. Gene therapy trials for the treatment of high-grade gliomas. Gene Ther Mol Biol 2007, 11:79-92.

46. Rueger MA, Winkelar A, Miletic H, Kaeoste C, Richter R, Schneider G, Hilk R, Heneka MT, Ernestus R, Hampel JA, Fraefel C, Jacobs AH. Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther 2003, 12:596-596.

47. Chena J, Bezdak T, Chang J, Kherraz AW, Willingham T, Azzara M, Nisen PD: A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res 1998, 58:3504-3507.

48. Weller M, Free K, Groccuth P, Kammers PH, Yonekawa Y, Fontana A: Improved HSV-1 amplicon packaging in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther 2003, 12:596-596.

49. Chen J, Bezdak T, Chang J, Kherraz AW, Willingham T, Azzara M, Nisen PD: A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res 1998, 58:3504-3507.

50. Bertrand J, Begaud-Grimaud G, Bessette B, Verdier M, Battu S, Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Improved HSV-1 amplicon packaging in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther 2003, 12:596-596.

51. Nagane M, Cavenee WK, Shiokawa Y: The sensitivity of human mesenchymal stem cells to ionizing radiation. J Neurosurg 2003, 99:297-300.

52. Suzuki M, Chiocca EA, Saeki Y: Expression of mutant non-cleavable Fas ligand on retrovirus packaging cells causes apoptosis of immunocompetent cells and improves prodigig activation gene therapy in a malignant glioma model. Life Sci 2003, 73:1847-1856.

53. Rubinchik S, Yu H, Woraratanaadharm J, Voelkel-Johnson C, Norns JS, Dong JY. Enhanced apoptosis of glioma cell lines is achieved by co-delivering Fasl-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther 2003, 10:814-822.

54. Muruve DA, Nicolson AG, Maniago RF, Strom TB, Sukhatme VP, Libermann TA. Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after Systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Hum Gene Ther 1997, 8:955-963.

55. Sonabend AM, Ulasov IV, Lesnai MS. Gene therapy trials for the treatment of high-grade gliomas. Gene Ther Mol Biol 2007, 11:79-92.

56. Rueger MA, Winkelar A, Miletic H, Kaeoste C, Richter R, Schneider G, Hilk R, Heneka MT, Ernestus R, Hampel JA, Fraefel C, Jacobs AH. Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther 2003, 12:596-596.

57. Chen J, Bezdak T, Chang J, Kherraz AW, Willingham T, Azzara M, Nisen PD: A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res 1998, 58:3504-3507.

58. Weller M, Free K, Groccuth P, Kammers PH, Yonekawa Y, Fontana A: Improved HSV-1 amplicon packaging in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther 2003, 12:596-596.

59. Chen J, Bezdak T, Chang J, Kherraz AW, Willingham T, Azzara M, Nisen PD: A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res 1998, 58:3504-3507.

60. Bertrand J, Begaud-Grimaud G, Bessette B, Verdier M, Battu S, Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Improved HSV-1 amplicon packaging in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther 2003, 12:596-596.

61. Nagane M, Cavenee WK, Shiokawa Y: The sensitivity of human mesenchymal stem cells to ionizing radiation. J Neurosurg 2003, 99:297-300.